Mast cell activation syndrome (MCAS) can produce a bewildering array of symptoms, from hives and flushing to gastrointestinal distress and anaphylaxis. Understanding the 7 root causes of mast cell activation syndrome is the first step toward managing this complex condition effectively. When mast cells become hyperreactive, they release excessive amounts of histamine, prostaglandins, leukotrienes, and other inflammatory mediators into surrounding tissue, causing symptoms that can affect virtually every organ system.
Researchers are still unraveling the full picture, but current evidence points to several key drivers. The 7 root causes of mast cell activation syndrome outlined below reflect the most well-supported mechanisms identified in peer-reviewed literature from institutions including the NIH, Mayo Clinic, and leading immunology research centers.
What Are Mast Cells and Why Do They Malfunction?
Before diving into root causes, it helps to understand what mast cells do under normal circumstances. Mast cells are immune cells found in connective tissues throughout the body, particularly in the skin, gut lining, airways, and around blood vessels. Their primary role is to detect threats such as pathogens, allergens, and toxins and mount an immediate inflammatory response.
When functioning properly, mast cells are essential for wound healing, fighting infections, and orchestrating immune defense. The problem in MCAS is that these cells become overactive, degranulating (releasing their chemical contents) in response to stimuli that should not trigger such a strong reaction, or even degranulating spontaneously without an identifiable trigger.
According to a consensus paper published in the Journal of Allergy and Clinical Immunology, MCAS is diagnosed when a patient meets three criteria: episodic symptoms consistent with mast cell mediator release affecting two or more organ systems, a documented increase in mast cell mediators (such as serum tryptase or urinary histamine metabolites), and response to medications that block or inhibit mast cell mediators. For a broader look at related conditions, visit our conditions guide.
1. Genetic Mutations in KIT and Other Receptors
The most well-established root cause of mast cell dysfunction involves mutations in the KIT gene, which encodes a receptor tyrosine kinase critical for mast cell development, survival, and activation. The D816V mutation in KIT is the hallmark of systemic mastocytosis, a related but distinct condition from MCAS. However, research published in Blood has identified other KIT variants and mutations in related signaling pathways that may contribute to MCAS without causing the clonal mast cell proliferation seen in mastocytosis.
Beyond KIT, researchers at the NIH have identified mutations in genes governing other mast cell receptors, including those for IgE (the antibody involved in allergic responses), complement receptors, and toll-like receptors. These genetic variations can lower the threshold for mast cell activation, meaning less stimulus is needed to trigger degranulation.
Hereditary alpha-tryptasemia (HaT), caused by extra copies of the TPSAB1 gene encoding alpha-tryptase, has also been linked to MCAS-like symptoms. A landmark study at the NIH found that HaT affects approximately 5 to 7 percent of the general population and is associated with elevated baseline tryptase levels, flushing, and multisystem complaints consistent with mast cell activation.
2. Chronic Infections and Immune Dysregulation
Chronic or latent infections can persistently stimulate mast cells, keeping them in a state of heightened reactivity. Several classes of infections have been linked to MCAS onset or worsening:
Tick-borne infections: Lyme disease (Borrelia burgdorferi) and co-infections such as Bartonella and Babesia have been associated with mast cell activation in clinical literature. Research suggests these organisms can directly activate mast cells through pattern recognition receptors, leading to sustained inflammatory signaling.
Viral infections: Epstein-Barr virus (EBV), cytomegalovirus (CMV), and SARS-CoV-2 have all been implicated in triggering or exacerbating MCAS. The emergence of MCAS symptoms following COVID-19 infection has been documented in multiple case series, and some researchers believe mast cell dysfunction contributes to long COVID symptoms.
Mold and biotoxin exposure: Chronic exposure to water-damaged buildings and mold species such as Aspergillus and Stachybotrys can activate mast cells through mycotoxins. Research from the International Journal of Molecular Sciences has demonstrated that mycotoxins can directly trigger mast cell degranulation.
Gut infections: Small intestinal bacterial overgrowth (SIBO), Helicobacter pylori, and parasitic infections can create chronic immune stimulation in the gut, where a large proportion of the body’s mast cells reside.
3. Gut Barrier Dysfunction (Intestinal Permeability)
The gut houses the largest concentration of mast cells in the body, and the integrity of the intestinal barrier plays a critical role in regulating mast cell behavior. When the gut lining becomes compromised, a condition sometimes referred to as increased intestinal permeability or “leaky gut,” partially digested food proteins, bacterial components (lipopolysaccharides), and other antigens can cross the barrier and interact directly with mucosal mast cells.
A study published in Gut demonstrated that patients with irritable bowel syndrome (IBS) had significantly increased mast cell numbers and activation in their intestinal mucosa, correlating with symptom severity. Research from the Cleveland Clinic has similarly linked mast cell activation in the gut to food sensitivities, abdominal pain, and diarrhea.
Factors that contribute to gut barrier dysfunction include chronic stress, nonsteroidal anti-inflammatory drugs (NSAIDs), alcohol, pesticide exposure, and dysbiosis (imbalanced gut microbiome). Restoring gut barrier integrity through dietary modifications, targeted probiotics, and removing offending agents is a cornerstone of many MCAS treatment protocols.
4. Environmental Toxin Exposure
Modern environmental exposures place increasing demands on the immune system, and mast cells are often on the front line of the response. Several categories of environmental toxins have been directly linked to mast cell activation:
Heavy metals: Mercury, lead, and cadmium have been shown to activate mast cells in laboratory studies. A review in Toxicology Letters found that mercury, in particular, promotes mast cell degranulation and increases histamine release through oxidative stress pathways.
Pesticides and herbicides: Organophosphate pesticides and glyphosate have been associated with immune dysregulation. Research suggests these chemicals can alter mast cell signaling and reduce the body’s ability to properly modulate immune responses.
Volatile organic compounds (VOCs): Formaldehyde, benzene, and other VOCs found in building materials, cleaning products, and personal care items can trigger mast cell activation in sensitive individuals. This is one reason why people with MCAS often report chemical sensitivity or multiple chemical sensitivity (MCS).
Endocrine disruptors: Bisphenol A (BPA), phthalates, and other endocrine-disrupting chemicals have been shown to influence mast cell behavior. A study published in Environmental Health Perspectives found that BPA exposure increased mast cell degranulation and histamine release in animal models.
5. Connective Tissue Disorders, Especially Ehlers-Danlos Syndrome
A striking clinical overlap exists between MCAS and connective tissue disorders, particularly hypermobile Ehlers-Danlos syndrome (hEDS). Research published in the American Journal of Medical Genetics has documented that patients with hEDS have significantly higher rates of MCAS compared to the general population. The triad of hEDS, MCAS, and postural orthostatic tachycardia syndrome (POTS) is so commonly observed that it has its own designation in clinical literature.
The mechanism linking connective tissue disorders to mast cell activation is not fully understood, but several hypotheses have been proposed. One theory suggests that abnormal collagen structure in connective tissue disorders creates a mechanical environment that promotes mast cell activation. Another proposes that shared genetic factors predispose individuals to both conditions simultaneously.
What is clear from clinical observation is that patients with hEDS are disproportionately affected by MCAS symptoms, and treatment of one condition often improves the other. Clinicians increasingly screen for MCAS when diagnosing hEDS and vice versa.
6. Nervous System Dysregulation and Chronic Stress
The nervous system and mast cells engage in extensive bidirectional communication. Mast cells are often found in close proximity to nerve endings, and neuropeptides such as substance P and corticotropin-releasing hormone (CRH) can directly trigger mast cell degranulation. This nerve-mast cell connection explains why stress, trauma, and nervous system dysregulation are among the root causes of MCAS.
Research published in the Journal of Neuroimmunology demonstrated that psychological stress increases mast cell activation in both the gut and the brain. Chronic stress elevates CRH levels, which not only activates mast cells but also increases their numbers in affected tissues.
Autonomic nervous system dysfunction, including dysautonomia and vagal nerve impairment, has also been linked to MCAS. When the vagus nerve, which normally exerts anti-inflammatory effects, is underactive, the brake on mast cell activation is weakened. This connection helps explain the overlap between MCAS and conditions like POTS, where autonomic dysfunction is a defining feature.
Trauma, both physical and psychological, can sensitize the nervous system in ways that perpetuate mast cell activation. Some practitioners incorporate vagus nerve stimulation, trauma-informed therapies, and nervous system regulation techniques (such as polyvagal-informed approaches) into MCAS treatment protocols alongside conventional medications.
7. Hormonal Imbalances and Fluctuations
Hormones exert powerful effects on mast cell behavior, and hormonal imbalances represent the seventh root cause of MCAS. This connection is most evident in the observation that MCAS symptoms disproportionately affect women and often fluctuate with the menstrual cycle, pregnancy, and menopause.
Estrogen: Research published in Allergy has shown that estrogen increases mast cell degranulation and enhances the synthesis of histamine. Mast cells express estrogen receptors, and rising estrogen levels during the follicular phase of the menstrual cycle correlate with increased MCAS symptoms in many women. This explains why some women experience flares of hives, flushing, and GI symptoms at predictable times in their cycle.
Progesterone: While progesterone generally has a calming effect on mast cells, some women develop progesterone hypersensitivity, where progesterone itself triggers mast cell activation. This autoimmune response to endogenous progesterone can cause cyclical anaphylaxis and other severe MCAS symptoms.
Thyroid hormones: Thyroid dysfunction, particularly autoimmune thyroiditis (Hashimoto’s), frequently co-occurs with MCAS. Thyroid hormones influence mast cell maturation and activation, and the autoimmune inflammation associated with thyroiditis can provide ongoing stimulation to local mast cells.
Cortisol: Cortisol is a natural mast cell stabilizer, and adrenal insufficiency or HPA axis dysfunction can remove this protective brake. When cortisol levels are chronically low or poorly regulated, mast cells become more reactive.
Frequently Asked Questions
Can MCAS be cured by addressing root causes?
While MCAS is generally considered a chronic condition, many patients achieve significant symptom improvement by identifying and addressing their specific root causes. For example, treating an underlying infection, restoring gut barrier integrity, reducing toxin exposure, or balancing hormones can meaningfully reduce mast cell reactivity. The degree of improvement varies by individual and depends on how many root causes are contributing and how reversible each one is.
How is MCAS different from mastocytosis?
Mastocytosis involves an abnormal proliferation (increase in number) of mast cells, usually driven by the D816V KIT mutation. MCAS, by contrast, typically involves mast cells that are normal in number but hyperactive in function. Both conditions produce symptoms from excessive mast cell mediator release, but mastocytosis is diagnosed through bone marrow biopsy showing mast cell clusters, while MCAS is diagnosed through mediator testing and clinical criteria.
What is the most common trigger for MCAS flares?
Triggers vary widely among individuals, but the most commonly reported triggers include certain foods (especially high-histamine foods), heat, stress, physical exertion, fragrances, medications (particularly NSAIDs and opioids), insect stings, and hormonal changes. Many MCAS patients find it helpful to keep a symptom diary to identify their personal trigger patterns.
Can children develop MCAS?
Yes. MCAS can affect people of all ages, including children. In pediatric cases, symptoms may present as unexplained abdominal pain, skin flushing, hives, frequent allergic-type reactions, or behavioral changes. Diagnosis can be more challenging in children because symptoms often overlap with common childhood conditions. Pediatric allergists and immunologists with experience in mast cell disorders are the most appropriate specialists for evaluation.
Key Takeaways
The 7 root causes of mast cell activation syndrome include genetic mutations in KIT and related receptors, chronic infections and immune dysregulation, gut barrier dysfunction, environmental toxin exposure, connective tissue disorders like EDS, nervous system dysregulation and chronic stress, and hormonal imbalances. Most MCAS patients have multiple contributing root causes rather than a single trigger. A comprehensive approach that identifies and addresses as many underlying drivers as possible offers the best chance for meaningful symptom improvement. Work with a healthcare provider experienced in MCAS to develop a personalized evaluation and treatment plan that goes beyond symptom management to address the deeper mechanisms driving your mast cell dysfunction.